There’s a lot to be optimistic about in the Consumer Goods sector as 2 analysts just weighed in on USANA Health (USNA) and Crocs (CROX) with bullish sentiments.
USANA Health (USNA)
In a report released today, Timothy Ramey from Pivotal Research reiterated a Buy rating on USANA Health, with a price target of $75. The company’s shares closed yesterday at $63.05, close to its 52-week low of $58.30.
Ramey commented:
“We thought it noteworthy that the company projected average diluted shares outstanding of 22.7 million, given that 2Q diluted shares out were 23.4 million. To get to that average we expect the company will need to buy-in 1.9 million shares in the 2H. That will put average shares outstanding down 7.7% for the year. This is not so important for 2019, but it will be for next year when we see an earnings recovery of 27% at the net income line (still below 2018) but EPS growth of 38% owing to the reduced share count.”
According to TipRanks.com, Ramey is a 4-star analyst with an average return of 6.0% and a 56.0% success rate. Ramey covers the Consumer Goods sector, focusing on stocks such as Constellation Brands Inc, Post Holdings Inc, and Brown-Forman B.
Currently, the analyst consensus on USANA Health is a Moderate Buy with an average price target of $71.67.
See today’s analyst top recommended stocks >>
Crocs (CROX)
Pivotal Research analyst Mitch Kummetz reiterated a Buy rating on Crocs today and set a price target of $35. The company’s shares closed yesterday at $23.39.
Kummetz commented:
“We believe that clogs demand was very strong for the quarter and suspect that this category was less supply constrained for 2Q than 1Q. On the other hand, we wouldn’t be surprised if unfavorable weather had some negative impact on CROX’s sandal performance. We also remain optimistic that CROX can exceed its FY19 guidance. BTS is a big hurdle, given robust clogs demand a year ago, but we believe recent data suggests that CROX is already tracking at a level ahead of last year’s peak BTS season, which we view as very encouraging. That said, CROX knows that BTS is a tough hurdle, so we’d be surprised if the company lifts its FY19 sales guidance on this print.”
According to TipRanks.com, Kummetz is a 3-star analyst with an average return of 2.8% and a 55.2% success rate. Kummetz covers the Services sector, focusing on stocks such as Foot Locker Inc, Shoe Carnival, and Genesco Inc.
Currently, the analyst consensus on Crocs is a Strong Buy with an average price target of $29.40, a 25.7% upside from current levels. In a report issued on July 15, Piper Jaffray also upgraded the stock to Buy with a $27 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
